Clinical Trial Update: PipEracillin/Tazobactam Versus mERoPENem for Treatment of AmpC Producing Blood Stream Infections [Phase 4]

View source ↗

Summary

A Phase 4 trial comparing pipercillin/tazobactam against meropenem for AmpC-producing bloodstream infections has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacteremia
• Enterobacteriaceae Infection

Drugs mentioned

• Meropenem (Meropenem)
• Piperacillin/tazobactam (Piperacillin/tazobactam)

Snippet

Sponsor: Rambam Health Care Campus | Conditions: Beta Lactam Resistant Bacterial Infection, Enterobacteriaceae Infections | Phase 4 | Status: WITHDRAWN